Journal of Neural Transmission

, Volume 122, Issue 3, pp 427–431 | Cite as

Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®

  • Katja Kollewe
  • Bahram Mohammadi
  • Steffen Köhler
  • Heidrun Pickenbrock
  • Reinhard Dengler
  • Dirk Dressler
Neurology and Preclinical Neurological Studies - Original Article


Botulinum toxin (BT) therapy is the treatment of choice for blepharospasm (BPS). Currently available BT type A drugs include Botox®, Dysport® and Xeomin®. Until now, there are few long-term studies on BT therapy for BPS. This is the first long-term study comparing all three major BT drugs. We collected treatment, efficacy and adverse effect data on BPS patients treated with either Botox®, Dysport® or Xeomin® for at least eight consecutive treatments. Two hundred and eighty-eight patients (208 females, 80 males, age 62 ± 12 years) were included in this study. The treatment time was 11.2 ± 4.1 years covering 10,701 injection series. Doses were 47 ± 10 MU for Botox®, 120 ± 35 MU for Dysport® and 62 ± 11 MU for Xeomin® (Botox® dose vs Xeomin® dose: p < 0.001, unpaired t test). 85 % of all patients had stable doses. The onset of the therapeutic effect was after 6.1 ± 3.3 days and its duration lasted 10.2 ± 3.5 weeks. The Global Clinical Improvement (GCI, 0 = no, 1 = slight, 2 = moderate, 3 = marked improvement in severity and function) as estimated by the patient was 2.5 ± 0.6. It was stable in 90 % of the patients. Adverse effect frequency was 3.0 % (ptosis 2.3 %, dry eye 0.5 %, diplopia 0.2 %). None of these findings was significantly different between Botox®, Dysport® and Xeomin®. Our study, one of the largest studies on BT therapy of BPS and the study with the longest follow-up, confirms that BT therapy produces robust clinical improvement which is stable throughout the treatment time. Therapeutic effects start after 6.1 days and last for about 10 weeks before they start to vanish. With this, they are approximately 2 weeks shorter than the recommended inter-injection interval. Adverse effects were rare, mild and always transient. BT therapy is a safe and effective treatment for BSP. Shorter inter-injection intervals may improve therapeutic results.


Blepharospasm Long-term treatment Botulinum toxin Botox® Xeomin® Dysport® 


  1. Ababneh OH, Cetinkaya A, Kulwin DR (2014) Long-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol 42(3):254–261Google Scholar
  2. Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A (2013) Dystonia rating scales: critique and recommendations. Mov Disord 28:874–883CrossRefPubMedCentralPubMedGoogle Scholar
  3. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo FS, Albanese A (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 15:224–231CrossRefPubMedGoogle Scholar
  4. Calace P, Cortese G, Piscopo R, Della VG, Gagliardi V, Magli A, De BT (2003) Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 13:331–336PubMedGoogle Scholar
  5. Cillino S, Raimondi G, Guepratte N, Damiani S, Cillino M, Di PF, Casuccio A (2010) Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye (Lond) 24:600–607CrossRefGoogle Scholar
  6. Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA (2013) Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol 156:173–177CrossRefPubMedGoogle Scholar
  7. Dressler D (2009) Routine use of Xeomin in patients pre-treated with Botox: long term results. Eur J Neurol 16(Suppl 2):2–5CrossRefPubMedGoogle Scholar
  8. Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin((R))): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385–389CrossRefPubMedGoogle Scholar
  9. Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38CrossRefPubMedGoogle Scholar
  10. Dressler D, Bigalke H (2004) Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 52:132–135CrossRefPubMedGoogle Scholar
  11. Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox(R)) and incobotulinumtoxinA (Xeomin (R)) in an LD50 assay. J Neural Transm 119:13–15CrossRefPubMedGoogle Scholar
  12. Dressler D, Tacik P, Adib SF (2014a) Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(R)) and incobotulinumtoxinA (Xeomin (R)). J Neural Transm 121:29–31CrossRefPubMedCentralPubMedGoogle Scholar
  13. Dressler D, Tacik P, Adib SF (2014b) Botulinum toxin therapy for cervical dystonia: duration of therapeutic effects. J Neural Transm. doi: 10.1007/s00702-014-1253-8
  14. Dutton JJ, Buckley EG (1988) Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 95:1529–1534CrossRefPubMedGoogle Scholar
  15. Dutton JJ, Fowler AM (2007) Botulinum toxin in ophthalmology. Surv Ophthalmol 52:13–31CrossRefPubMedGoogle Scholar
  16. Frevert J (2009) Xeomin is free from complexing proteins. Toxicon 54:697–701CrossRefPubMedGoogle Scholar
  17. Frueh BR, Callahan A, Dortzbach RK, Wilkins RB, Beale HL, Reitman HS, Watson FR (1976) The effects of differential section of the VIITH nerve on patients with intractable blepharospasm. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 81:OP595–OP602PubMedGoogle Scholar
  18. Gil PC, Rodriguez Sanz MF, Berrocal IN, Castrillo SA, Gutierrez RR, Zamora Garcia MI, Mendoza RA, Duarte Garcia-Luis J (2013) Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin. Neurologia 28:131–136CrossRefGoogle Scholar
  19. Gill HS, Kraft SP (2010) Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can J Neurol Sci 37:631–636CrossRefPubMedGoogle Scholar
  20. Grandas F, Elston J, Quinn N, Marsden CD (1988) Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767–772CrossRefPubMedCentralPubMedGoogle Scholar
  21. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288–1293CrossRefPubMedGoogle Scholar
  22. Jankovic J, Ford J (1983) Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 13:402–411CrossRefPubMedGoogle Scholar
  23. Kenney C, Jankovic J (2008) Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 115:585–591CrossRefPubMedGoogle Scholar
  24. Kollewe K, Mohammadi B, Dengler R, Dressler D (2010) Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm 117:759–763CrossRefPubMedGoogle Scholar
  25. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31:463–466CrossRefPubMedGoogle Scholar
  26. Mohammadi B, Balouch SA, Dengler R, Kollewe K (2010) Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients. Neurol Res 32:309–313CrossRefPubMedGoogle Scholar
  27. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ III (1988) Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3:188–194CrossRefPubMedGoogle Scholar
  28. Rollnik JD, Matzke M, Wohlfarth K, Dengler R, Bigalke H (2000) Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol 43:9–12CrossRefPubMedGoogle Scholar
  29. Silveira-Moriyama L, Goncalves LR, Chien HF, Barbosa ER (2005) Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq Neuropsiquiatr 63:221–224CrossRefPubMedGoogle Scholar
  30. Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH (2013) Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin (R)) injections in blepharospasm. J Neural Transm 120:1345–1353CrossRefPubMedCentralPubMedGoogle Scholar
  31. Vogt T, Lussi F, Paul A, Urban P (2008) Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Nervenarzt 79:912–917CrossRefPubMedGoogle Scholar
  32. Wabbels B, Jost WH, Roggenkamper P (2011) Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neural Transm 118:925–943CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  • Katja Kollewe
    • 1
  • Bahram Mohammadi
    • 2
    • 3
  • Steffen Köhler
    • 1
  • Heidrun Pickenbrock
    • 1
  • Reinhard Dengler
    • 1
  • Dirk Dressler
    • 1
  1. 1.Movement Disorders Section, Department of NeurologyHannover Medical SchoolHannoverGermany
  2. 2.Department of NeurologyUniversity Hospitals Schleswig-HolsteinLuebeckGermany
  3. 3.International Neuroscience Institute (INI)HannoverGermany

Personalised recommendations